Navigation Links
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/27/2008

accounts

receivable 24,318 (34,654)

Decrease (increase) in inventories 1,503 3,971

Decrease (increase) in other assets 7,443 1,095

Increase (decrease) in accounts

payable (3,147) (8,926)

Increase (decrease) in accrued

compensation 986 3,581

Increase (decrease) in accrued

expenses 36,151 5,503

Increase (decrease) in interest

payable (1,176) 23

Increase (decrease) in deferred

revenue 40,863 16,245

Increase (decrease) in other

liabilities (190) 4,310

Net cash provided by (used in)

operating activities 146,302 (92,715)

Cash flows from investing activities:

Purchases of property and equipment (32,796) (22,524)

Purchases of investments (593,118) (502,230)

Sales of investments 2,057 2,252

Maturities of investments 591,202 405,622

Net cash provided by (used in)

investing activities (32,655) (116,880)

Cash flows from financing activities:

Issuance of common stock, net of

issuance costs 3,780 22,259

Payments of loan and capital lease

obligations (2,895) (10,488)

Repayments of convertible

subordinated notes (102,653) -

Net cash provided by
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3JAG Media Holdings Inc Amends Articles of Incorporation 58781 1JAG Media Holdings Inc Amends Articles of Incorporation 58781 2Vermillion Announces Return of Eric Fung M D Ph D 14338 1Vermillion Announces Return of Eric Fung M D Ph D 14338 2Vermillion Announces Return of Eric Fung M D Ph D 14338 3Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 1Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 2